Oral sodium bicarbonate to reduce contrast induced nephropathy

Oral sodium bicarbonate to reduce contrast induced nephropathy in the out-patient coronary angiogram population - a randomised, double blinded study in patients with renal impairment

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12608000205336

Enrollment

100

Registered

2008-04-16

Start date

2008-04-10

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Sodium bicarbonate capsules (840mg) - doses given day prior to coronary angiography and on the day of procedure. This is on top of routine pre-angiography intravenous hydration.

Study design

Allocation

Randomised controlled trial

Intervention model

Parallel

Primary purpose

Prevention

Masking

Blinded (masking used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Estimated glomerular filtration rate < 60mL/min Adults > 18years old Able to provide informed consent Awaiting elective coronary angiography

Exclusion criteria

New York Heart Association III or IV Acute myocardial infarction Acute pulmonary oedema Pregnancy Renal replacement therapy Medical kidney disease (multiple myeloma, acute nephritis) Prior use of N-acetylcysteine or sodium bicarbonate or intravenous contrast agent in the preceding 4 weeks

Outcome results